Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: A phase II study

European Journal of Cancer Part A

Volumn 32, Issue 13, 1996, Pages 2229-2235

  Sanson, M ^d   Ameri, A ^d   Monjour, A ^b   Sahmoud, T ^c   Ronchin, P ^a   Poisson, M ^d   Delattre, J Y ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Hopital Louis Pasteur   (France)

^c European Organisation for Research   (Belgium)

^d NONE

Author keywords

Carboplatin; Etoposide; Gliomas; Ifosfamide; Phase II study

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SUPRATENTORIAL NEOPLASMS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0030445597     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00299-7     Document Type: Article

References (43)

1. 1. Canetta R, Rozencweig M, Carter S. Carboplatin: the clinical spectrum to date. Cancer Treat Rev 1985, 12, 125-136.
2. 2. Boven E, Van Der Vijgh WJF, Nauta MM, Schlüper HMM, Pinedo HM. Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts. Cancer Res 1985, 45, 86-90.
3. 3. Dodion P, Sanders C, Georges P, Kenis Y. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 1988, 22, 80-82.
4. 4. Allen JC, Walker R, Luks E, Jenning M, Barfoot Tan C. Carboplatin and recurrent childhood brain tumours. J Clin Oncol 1987, 5, 459-463.
5. 5. Follezou JY, Fauchon F, Chiras J. Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study. Neoplasma 1989, 36, 349-352.
6. 6. Twelves CJ, Ash CM, Miles DW, Thomas DGT, Souhami RL. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991, 27, 481-483.
7. 7. Poisson M, Pereon Y, Chiras J, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neuro Oncol 1991, 10, 139-144.
8. 8. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991, 9, 860-864.
9. 9. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985, 312, 692-700.
10. 10. Aisner J, Lee EJ. Etoposide: current and future status. Cancer 1991, 67, 215-219.
11. 11. Drewinko B, Green C, Loo TL. Combination chemotherapy in vitro with cis-dichlorodiammineplatinium. Cancer Treat Rep 1976, 60, 1619-1625.
12. 12. Boiardi A, Silvani A, Milanesi I, Botturi M, Broggi G. Primary glial tumor patients treated by combining cis-platin and etoposide. J Neuro Oncol 1991, 11, 165-170.
13. 13. Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992, 10, 1074-1077.
14. 14. Ameri A, Poisson M, Chauveinc L, Chen QM, Delattre JY. Treatment of recurrent malignant supratentorial glioms with association of carboplatin and etoposide: a phase II study [abstract]. Neurology 1993, 43(Suppl.), 248.
15. 15. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988, 80, 556-566.
16. 16. Loehrer PJ. The history of Ifosfamide. Semin Oncol 1992, 19(Suppl. 12), 2-7.
17. 17. Loehrer PJ, Lauer P, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastin or etoposide. Ann Intern Med 1988, 7, 540-546.
18. 18. Schabel FM, Trader MW, Laser WR, et al. Cisdichlorodiammineplatinum (II): combination chemotherapy and cross resistance studies with tumors of mice. Cancer Treat Rep 1979, 63, 1459-1473.
19. 19. Goldin A. Ifosfamide in experimental tumor systems. Semin Oncol 1982, 9, 14-23.
20. 20. Marina NN, Radman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with Ifosfamide and Etoposide in children with relapsed solid tumors. J Clin Oncol 1993, 11, 554-560.
21. 21. Siegert W, Beyer J, Strohscheer I, et al. High dose treatment with Carboplatin, Etoposide, and Ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994, 12, 1223-1231.
22. 22. Fields KK, Perkins JP, Hiemens JW, et al. Intensive dose ifosfamide, carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. Surg Oncol 1993, 2, 87-95.
23. 23. Richardson DS, Tighe M, Cull G, Johnson SA, Phillips MJ. Salvage chemotherapy for relapsed and resistant lymphoma with carboplatin containing schedule EPIC. Hematol Oncol 1994, 12, 125-128.
24. 24. Thatcher N. Ifosfamide/Carboplatin/Etoposide (ICE) regimen in small cell lung cancer. Lung 1993, 9, 51-57.
25. 25. Hsieh Rk, Chang Ay, Boros L, Asbury R. Phase II study of Ifosfamide, Carboplatin, and Etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol 1994, 17, 509-513.
26. 26. Simon R. Optimal two-stage designs for phase II clinical trails. Controlled Clinical Trials 1989, 10, 1-10.
27. 27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457-481.
28. 28. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8, 1277-1280.
29. 29. Burger PC. Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment. Semin Oncol 1986, 13, 16-26.
30. 30. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro Oncol 1994, 19, 69-74.
31. 31. Elliott TE, Buckner JC, Cascino TI, Levitt R, O'Fallon JR, Scheithauer BW. Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neuro Oncol 1991, 10, 27-30.
32. 32. Chastagner P, Sommelet-Olive D, Kalifa C, et al. Phase II study of ifosfamide in childhood brain tumors: a report by the French Society of Pediatric Oncology (SFOP). Med Ped Oncol 1993, 21, 49-53.
33. 33. Pratt CB, Douglass EC, Kovnar AH, et al. A phase I study of Ifosfamide given on alternate days to treat children with brain tumors. Cancer 1993, 71, 3666-3669.
34. 34. Heideman RL, Douglass EC, Langston JA, et al. A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a pediatric oncology group study. J Neuro Oncol 1995, 25, 77-84.
35. 35. Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/VP16 combination in the treatment of recurrent malignant solid tumors of childhood: a POG Phase II study. Cancer 1993, 71, 1898-1903.
36. 36. Miser J, Krailo M, Smithson W, Belasco J, Ortega J, Hammond GD. Treatment of children with recurrent brain tumors with ifosfamide (IFOS) etoposide (VP16) and mesna (M). Results of a phase II trial (Abstract). Proc Am Soc Clin Oncol 1989, 8, 84.
37. 37. Rodriguez LA, Prados M, Silver P, Levin VA. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989, 64, 2420-2423.
38. 38. Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 1990, 40, 1743-1746.
39. 39. Longee DC, Friedman HS, Albright RE, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990, 72, 583-588.
40. 40. Taylor SA, Crowley J, Pollock TW, et al. Objective antitumor activity of Acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial. J Clin Oncol 1991, 9, 1476-1479.
41. 41. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992, 10, 766-771.
42. 42. Ameri A, Poisson M, Chen QM, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neuro Oncol 1993, 17, 43-46.
43. 43. Newton HB, Bromberg J, Junck L, Page MA, Greenberg HS. Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. J Neuro Oncol 1993, 15, 257-263.